Gkikas Andreas, Lampridis Savvas, Patrini Davide, Kestenholz Peter B, Azenha Luis Filipe, Kocher Gregor Jan, Scarci Marco, Minervini Fabrizio
Department of Cardiothoracic Surgery, Royal Victoria Hospital, Belfast, United Kingdom.
Department of Thoracic Surgery, 424 General Military Hospital, Thessaloniki, Greece.
Front Surg. 2022 Mar 8;9:848972. doi: 10.3389/fsurg.2022.848972. eCollection 2022.
Thoracic outlet syndrome (TOS) is a pathological condition caused by a narrowing between the clavicle and first rib leading to a compression of the neurovascular bundle to the upper extremity. The incidence of TOS is probably nowadays underestimated because the diagnosis could be very challenging without a thorough clinical examination along with appropriate clinical testing. Beside traditional supra-, infraclavicular or transaxillary approaches, the robotic assisted first rib resection has been gaining importance in the last few years.
We conducted a retrospective cohort analysis of all patients who underwent robotic assisted first rib resection due to TOS at Lucerne Cantonal Hospital and then we performed a narrative review of the English literature using PubMed, Cochrane Database of Systematic Reviews and Scopus.
Between June 2020 and November 2021, eleven robotic assisted first rib resections were performed due to TOS at Lucerne Cantonal Hospital. Median length of stay was 2 days (Standard Deviation: +/- 0.67 days). Median surgery time was 180 min (Standard Deviation: +/- 36.5). No intra-operative complications were reported.
Robotic assisted first rib resection could represent a safe and feasible option in expert hands for the treatment of thoracic outlet syndrome.
胸廓出口综合征(TOS)是一种由锁骨和第一肋骨之间狭窄导致上肢神经血管束受压引起的病理状况。如今,TOS的发病率可能被低估了,因为如果没有全面的临床检查以及适当的临床测试,诊断可能极具挑战性。除了传统的锁骨上、锁骨下或经腋窝入路外,机器人辅助第一肋骨切除术在过去几年中变得越来越重要。
我们对卢塞恩州立医院因TOS接受机器人辅助第一肋骨切除术的所有患者进行了回顾性队列分析,然后使用PubMed、Cochrane系统评价数据库和Scopus对英文文献进行了叙述性综述。
2020年6月至2021年11月期间,卢塞恩州立医院因TOS进行了11例机器人辅助第一肋骨切除术。中位住院时间为2天(标准差:±0.67天)。中位手术时间为180分钟(标准差:±36.5)。未报告术中并发症。
在专家手中,机器人辅助第一肋骨切除术可能是治疗胸廓出口综合征的一种安全可行的选择。